EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …

8502 Background: Median Overall survival (mOS) of stage IIIA resected NSCLC was 59.4
months (m) in CTONG 1104 adj gefitinib and 26.2 m in SAKK neoadjuvant chemo trial …

PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …

Background: Cisplatin-based doublet chemotherapy as neoadjuvant treatment for IIIA-N2
non-small cell lung cancer (NSCLC) give patients 5% survival benefit. EGFR-TKIs have …

Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …

Background Neoadjuvant erlotinib and customized adjuvant therapy are appealing but
controversial. The purpose of this study was to evaluate the role of biomarker-guided …

Abstract The Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis and the meta-
analysis of individual participant data reported by non-small cell lung cancer (NSCLC) Meta …

Background The optimal neoadjuvant regimen for locally advanced resectable non-small
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …

Whether the success of EGFR TKIs in the advanced setting could transfer to adjuvant setting
for patients with early-stage disease attracts much more attention. The use of EGFR TKI …

9005 Background: ADJUVANT-CTONG1104, a randomized phase 3 trial showed adjuvant
gefitinib treatment significantly improved disease-free survival (DFS) vs standard doublet …